ML-T7
Based on 1 Customer Validation
ML-T7 is a potent Tim-3 inhibitor. ML-T7 blocks Tim-3 interactions with PtdSer and CEACAM1. ML-T7 not only enhances the antitumor activity of adoptive transfer therapy with cytotoxic T lymphocytes (CTLs) and CAR T cells but also increases the effector function of T cell. ML-T7 promotes NK cells’ killing activity against tumor cells and DC antigen-presenting capacity. ML-T7 directly exerts antitumor efficacy in preclinical tumor models either alone or in combination with Nivolumab (HY-P9903A). ML-T7 can be used for tumor immunotherapy research.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.93%
- CAS. Nr.: 459789-75-4
- Formel: C27H17Cl2NO5
- Molecular Weight:506.33
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
ML-T7(10 μM, 0-6 days) enhances TCR/STAT5 signaling and promotes CD8+ cell antitumor activity through Tim-3[1].
ML-T7(10 μM, 24 h) promotes DC maturation and function through Tim-3 and Tim-4, enhances DC antigen-presenting ability[1].
ML-T7(10 μM, 24 h) enhances CTL activation and cytokine production, decreases apoptosis of CTLs[1].
ML-T7(10 μM, 48 h) significantly enhances the production of IFN-γ, TNF-α, CD107a, and granzyme B in human NK cell line NK92 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:CD8+ cell
-
Concentration:10 μM
-
Incubation Time:0-6 days
-
Result:Increased the phosphorylation of phospholipase C–γ1(PLC-γ1), ZAP70, LCK, ERK1/2, and STAT5 upon anti-CD3/CD28 stimulation.
-
Cell Line:Bone Marrow Cells
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Increased the expression of DC maturation markers.
ML-T7 (20 mg/kg; Intraperitoneal injection; every 2 days, 10 times) synergizes with Nivolumab (HY-P9903A) to improve the antitumor efficacy of Nivolumab (HY-P9903A) antibodies, and effectively improves HCC mice survival[1].
ML-T7 (50 mg/kg, Intraperitoneal injection; every 2 days for 3 weeks)shows a good safety profile in mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:10-week-old mice with spontaneous orthotopic HCC[1]
-
Dosage:10-50 mg/kg
-
Administration:Intraperitoneal injection (i.p.), every 2 days, 10 times
-
Result:Increased CD8+ T cells in both tumor and spleen. Inhibited T cell exhaustion. Promoted the function of CTLs, NK cells, and DCs.
-
Animal Model:10-week-old mice with orthotopic Akt/c-Myc HCC[1]
-
Dosage:20 mg/kg
-
Administration:Intraperitoneal injection (i.p.), every 2 days, 10 times
-
Result:Indicated stronger antituomr activity when treated with ML-T7 and Nivolumab (HY-P9903A). Rejuvenated NK cells by the combination therapy. Inhibited the accumulation of MDSCs and Tregs.
Chemical Information
-
CAS. Nr. 459789-75-4
-
Appearance Solid
-
Molecular Weight 506.33
-
Formel C27H17Cl2NO5
-
Color White to yellow
-
SMILES
O=C1C2=C(C(C13OC(C4C(N(C5=CC=C(C=C5Cl)Cl)C(C43)=O)=O)C6=CC=C(C)C=C6)=O)C=CC=C2
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Lösungsmittel & Löslichkeit
DMSO : 66.67 mg/mL (131.67 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Reinheit & Dokumentation
-
Data Sheet (285 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
Verweise
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9750 mL | 9.8750 mL | 19.7500 mL | 49.3749 mL |
| 5 mM | 0.3950 mL | 1.9750 mL | 3.9500 mL | 9.8750 mL | |
| 10 mM | 0.1975 mL | 0.9875 mL | 1.9750 mL | 4.9375 mL | |
| 15 mM | 0.1317 mL | 0.6583 mL | 1.3167 mL | 3.2917 mL | |
| 20 mM | 0.0987 mL | 0.4937 mL | 0.9875 mL | 2.4687 mL | |
| 25 mM | 0.0790 mL | 0.3950 mL | 0.7900 mL | 1.9750 mL | |
| 30 mM | 0.0658 mL | 0.3292 mL | 0.6583 mL | 1.6458 mL | |
| 40 mM | 0.0494 mL | 0.2469 mL | 0.4937 mL | 1.2344 mL | |
| 50 mM | 0.0395 mL | 0.1975 mL | 0.3950 mL | 0.9875 mL | |
| 60 mM | 0.0329 mL | 0.1646 mL | 0.3292 mL | 0.8229 mL | |
| 80 mM | 0.0247 mL | 0.1234 mL | 0.2469 mL | 0.6172 mL | |
| 100 mM | 0.0197 mL | 0.0987 mL | 0.1975 mL | 0.4937 mL |
Powered by Bioz